Reata Pharmaceuticals (United States)

Genetic and pharmacologic inhibition of Keap1 dampens the pro-fibrotic program in human hepatic stellate cells

Abstract The increasing prevalence of chronic liver diseases (CLDs) is a global health concern. CLDs can cause fibrosis, and there is an urgent need for antifibrotic agents. The primary driver of fibrogenesis, transforming growth factor beta 1 (TGF-β1), activates hepatic stellate...